Latest posts tagged with #KCSM on Bluesky
WATCH 👀: @drchoueiri.bsky.social of @danafarber.bsky.social
discusses the potential clinical effects of data from the phase 3 LITESPARK-022 study. #kcsm #oncology #GU26 See the whole video here 📷: www.onclive.com/view/dr-chou...
Day 2 of the 19th Annual NY GU Cancers Congress is in full swing! Check out onclive.com for all of our coverage of the meeting #oncology #kcsm #RCC #prostatecancer
WATCH 👀: @drchoueiri.bsky.social of @danafarber.bsky.social discusses safety data from the phase 3 LITESPARK-022 study in ccRCC. #kcsm #oncology #GU26
See the whole video here 📷: www.onclive.com/view/dr-chou...
Things are in full swing at the 19th Annual NY GU Cancers Congress! Check back at onclive.com for all of our coverage of the meeting #oncology #medtwitter #kcsm #GUcancer
🧬 Experts unpack practice-shaping data in RCC, urothelial, & prostate cancer from the 2026 Genitourinary Cancers Symposium — including updates on LITESPARK-022, KEYNOTE-B15, SunRISE-2 & PEACE-3 📊
#GU26 #oncology #medtwitter #kcsm #pcsm
Check it out 👉 www.onclive.com/view/experts...
sNDA Seeking Approval Belzutifan Plus Pembrolizumab in ccRCC Earns Priority Review From FDA
#kcsm #oncology
www.onclive.com/view/snda-se...
SBRT Plus Nivolumab/Ipilimumab Fails to Improve PFS in Advanced RCC @ascocancer.bsky.social #GU26 #kcsm www.onclive.com/view/sbrt-pl...
Depth of Response With Cabozantinib/Nivolumab Linked to Prolonged Survival Benefit in Advanced, Untreated RCC @ascocancer.bsky.social #GU26 #kcsm www.onclive.com/view/depth-o...
📹Watch Shilpa Gupta, MD, of @clevelandclinic.bsky.social discuss findings from an exploratory analysis from the phase 3 EV-302 trial presented during @ascocancer.bsky.social #GU26 #oncology #kcsm #RCC
We are back on site at the Moscone West in San Francisco for the final day of @ascocancer.bsky.social #GU26 Stop by room 2004 if you are interested in participating in an interview and check out hubs.li/Q0454Jtf0 for our full coverage! #oncology #kcsm #RCC #ASCOGU2026
Happening now at #GU26: in our latest Science in Seconds, Dr. Sumanta Pal breaks down LITESPARK-011 & 022 and possible impacts on care for patients with #kidneycancer
https://www.asco.org/abstracts-presentations/256660
https://www.asco.org/abstracts-presentations/256659
#rcc #kcsm
📹Sahil D. Doshi, MD, discusses data from an analysis of outcomes by number of doses of ipilimumab plus ivolumab first-line RCC that were presented during the 2026 Genitourinary Cancers Symposium. #GU26 #oncology #RCC #kcsm
🎥 This year at @ascocancer.bsky.social #GU26, we asked our interviewees which abstracts they were most looking forward to seeing at the meeting and their must-have food or drink for a conference!
#oncology #RCC #kcsm #GUcancer #ASCOGU2026
Hear what they had to say below:
Real-World SEER Data Highlight Age-Related Survival Gap in ICI-Treated Advanced RCC #kcsm #oncology
www.onclive.com/view/real-wo...
Nephrectomy after HIF-2α antagonist therapy is feasible and safe. From @renalurologynews.bsky.social.
https://bit.ly/48N2Sdj
#kidneycancer #kcsm
I just heard this on the local Jazz station #KCSM for their Latin Jazz show. It's some #DoctorDemento level stuff. And yes, the performer is Lalo Guerrero, was a Latino musician and farm labor activist (and a goofy guy!)
www.youtube.com/watch?v=iuL8...
Real-World Data Showcase Efficacy of Adjuvant Pembrolizumab in ccRCC #ESMO25 #kcsm #oncology www.onclive.com/view/real-wo...
Belzutifan Maintains Efficacy After a PD-(L)1 Inhibitor and Multiple VEGFR TKIs in ccRCC
#kcsm #oncology
www.onclive.com/view/belzuti...
Belzutifan Maintains High, Durable Responses in VHL Disease–Associated Neoplasms At 5 Years #SUO2025 #SUO25 #kcsm #oncology #medtwitter
www.onclive.com/view/belzuti...
Adjuvant Pembrolizumab Delivers Long-Term Benefits in ccRCC at Increased Risk of Recurrence @pennmedicine.bsky.social #SUO2025 #SUO25 #kcsm #oncology www.onclive.com/view/adjuvan...
This episode of OncLive On Air was filmed LIVE at #CFS25! Hear @benlevylungdoc.bsky.social & Dr Tagawa highlight developments in GU cancer management. Watch the video on our site, or listen wherever you get your podcasts! @weillcornell.bsky.social #kcsm #pcsm
www.onclive.com/view/psma-th...
Immunotherapy Resistance in Kidney Cancer Driven by Myeloid Cell Signaling @vanallenlab.bsky.social @danafarber.bsky.social #kcsm #oncology
www.onclive.com/view/immunot...
Emmanuel Seront, MD, PhD, discusses the Phase II RENALUT trial of 177Lu-PSMA-617 in metastatic ccRCC post-TKI/IO therapy, exploring PSMA-targeted radioligand therapy as a new option for resistant disease
🎥 buff.ly/dLhijGf
#KidneyCancer #KCSM #CTSM #TrialUpdate #RadioligandTherapy #RadOnc #ESMO25
Adjuvant Durvalumab Plus Tremelimumab Yields DFS Advantage in Resected RCC @myesmo.bsky.social #ESMO2025 #ESMO25 #kcsm #oncology
www.onclive.com/view/adjuvan...
Clara Steiner, MD, presents new transcriptomic findings from COSMIC-313 in #RCC at #ESMO25
🧬 RNA sequencing of baseline tumors
🔍 Distinct gene signatures by metastasis site
🌡️ Pathways: metabolism, hypoxia, EMT
🎥 Watch: buff.ly/dIMvnoC
@myesmo.bsky.social #KCSM #CTSM #TrialUpdate #UroOnc #UroSoMe
@stevenaleach I'll boost anyone talking about #KCSM!
An audio oddity: I don't listen to most modern music and rarely listen to music at all. It all sounds too synthy/autotuned/looped/artificial.
But lately I've had #KCSM #Jazz playing on my phone at work - and multiple people have walked through and been confused "I keep hearing this sound.." […]
Nemvaleukin Alfa Demonstrates Durable Disease Control in Advanced Melanoma and RCC #melsm #kcsm #oncology www.onclive.com/view/nemvale...
Defects in Antitumor Immunity May Account for Limited Efficacy With Checkpoint Inhibition in Chromophobe RCC
@braunmdphd.bsky.social @yalecancer.bsky.social #ChromophobeRCC #kcsm
www.onclive.com/view/defects...
